A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease
HC Wiesenfeld, LA Meyn, T Darville… - Clinical Infectious …, 2021 - academic.oup.com
HC Wiesenfeld, LA Meyn, T Darville, IS Macio, SL Hillier
Clinical Infectious Diseases, 2021•academic.oup.comBackground Anaerobic organisms are important pathogens in acute pelvic inflammatory
disease (PID). The currently recommended PID regimen of a single dose of ceftriaxone and
doxycycline for 14 days has limited anaerobic activity. The need for broader anaerobic
coverage is unknown and concerns have been raised about metronidazole tolerability.
Methods We conducted a randomized, double-blind, placebo-controlled trial comparing
ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days, with or without …
disease (PID). The currently recommended PID regimen of a single dose of ceftriaxone and
doxycycline for 14 days has limited anaerobic activity. The need for broader anaerobic
coverage is unknown and concerns have been raised about metronidazole tolerability.
Methods We conducted a randomized, double-blind, placebo-controlled trial comparing
ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days, with or without …
Background
Anaerobic organisms are important pathogens in acute pelvic inflammatory disease (PID). The currently recommended PID regimen of a single dose of ceftriaxone and doxycycline for 14 days has limited anaerobic activity. The need for broader anaerobic coverage is unknown and concerns have been raised about metronidazole tolerability.
Methods
We conducted a randomized, double-blind, placebo-controlled trial comparing ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days, with or without 14 days of metronidazole in women with acute PID. The primary outcome was clinical improvement at 3 days following enrollment. Additional outcomes at 30 days following treatment were the presence of anaerobic organisms in the endometrium, clinical cure (absence of fever and reduction in tenderness), adherence, and tolerability.
Results
We enrolled 233 women (116 to metronidazole and 117 to placebo). Clinical improvement at 3 days was similar between the 2 groups. At 30 days following treatment, anaerobic organisms were less frequently recovered from the endometrium in women treated with metronidazole than placebo (8% vs 21%, P < .05) and cervical Mycoplasma genitalium was reduced (4% vs 14%, P < .05). Pelvic tenderness was also less common among women receiving metronidazole (9% vs 20%, P < .05). Adverse events and adherence were similar in each treatment group.
Conclusions
In women treated for acute PID, the addition of metronidazole to ceftriaxone and doxycycline was well tolerated and resulted in reduced endometrial anaerobes, decreased M. genitalium, and reduced pelvic tenderness compared to ceftriaxone and doxycycline. Metronidazole should be routinely added to ceftriaxone and doxycycline for the treatment of women with acute PID.
Clinical Trials Registration
NCT01160640.
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果